Open Label Safety and Tolerability Trial of CPP-109 (Vigabatrin) in Adults With Treatment Refractory Tourette's Disorder

Trial Profile

Open Label Safety and Tolerability Trial of CPP-109 (Vigabatrin) in Adults With Treatment Refractory Tourette's Disorder

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Vigabatrin (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 27 Oct 2015 Results will be presented at the 62nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry 2015, according to Catalyst Pharmaceuticals, Inc. media release.
    • 22 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Jun 2015 Top-line results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top